Stirling reports positive preliminary trial results

By Melissa Trudinger
Tuesday, 30 November, 2004

Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.

Final results from the trial, which was conducted in the US by the USDA's Swine Research Unit, will be released early in 2005. The trial was designed to measure physiological and behavioural parameters including weight gain, feed conversion, increase in lean meat and decrease in fat content.

Related News

Sleep apnoea patients who use CPAP live longer: study

CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd